AstraZeneca

Living with a rare disease is inherently inequitable. That’s why at #Expo25 in Japan our team prioritised shining a light on solutions to help patients receive a diagnosis sooner.

Stigma still affects many living with lung cancer, creating potential barriers to timely diagnosis and care. The experiences of Clinton, Barbara, and Nancy highlight the need to challenge misconceptions and support those impacted by lung cancer. Explore their stories: https://learn.az/6040fXora #WorldLungCancerDay #PatientStory

We have been recognised for our efforts in lab sustainability through our continued success in the My Green Lab and the I2SL: International Institute for Sustainable Laboratories Freezer Challenge. Find out more about our Green Labs programme: https://learn.az/6043fn1XJ #WhatScienceCanDo #MyGreenLabs

#News for #Investors and #Media📈 Our H1 results are now available and show strong momentum, with Total Revenue up 11% and remarkable pipeline delivery. This progress reflects the ongoing dedication of our teams to improve the health of people, society and the planet. https://learn.az/6041fRVuR #AZN #FinancialResults

The climate crisis is one of the largest public health crises of our time. 🌎 It contributes to increased prevalence of respiratory illnesses, which are often complex, difficult to treat and poorly controlled, leading to a higher carbon footprint of care. Learn how we are leading the way in reducing this burden by transitioning to pressurised metered-dose inhalers (pMDIs) with a near-zero Global Warming Potential propellant. https://learn.az/6044fPSlQ

Important update: We will share our H1 and Q2 2025 performance update at 07:00 BST on Tuesday 29 July 2025.   An accompanying webcast for investors and analysts will take place at 14:00 BST – you can register to attend virtually here: https://lnkd.in/eVcJJ-Ar

#News Today we announced plans to invest $50 billion in medicines manufacturing and R&D in the United States by 2030. This landmark investment supports our ambition to achieve $80 billion in total revenue by that year, with 50% expected to be generated in the US. Our plans include a new, state-of-the-art drug substance manufacturing facility focused on chronic diseases in the Commonwealth of Virginia—the largest single manufacturing investment we’ve ever made—underpinning our belief in America’s innovation in biopharmaceuticals and our commitment to deliver our innovative medicines to millions more patients. #AZN #WhatScienceCanDo

#News Today we announced plans to invest $50 billion in medicines manufacturing and R&D in the United States by 2030. This landmark investment supports our ambition to achieve $80 billion in total revenue by that year, with 50% expected to be generated in the US. Our plans include a new, state-of-the-art drug substance manufacturing facility focused on chronic diseases in the Commonwealth of Virginia—the largest single manufacturing investment we’ve ever made—underpinning our belief in America’s innovation in biopharmaceuticals and our commitment to deliver our innovative medicines to millions more patients. #AZN #WhatScienceCanDo

Collaboration is at the heart of our progress and shapes our future. Our decade-long partnership with University of Cambridge advances innovation and strengthens Cambridge's science ecosystem. Find the impact report link in the comments👇 #WhatScienceCanDo

In collaboration with academia and industry partners, we are delighted to share our latest article, published in Nature Reviews Drug Discovery. This insightful analysis explores pivotal shifts from the last two decades in key physicochemical properties and optimization strategies in the development of innovative drug candidates, and where the future is headed. Read more: https://learn.az/60474NuoH #WhatScienceCanDo #MedicinalChemistry